Trending Topic

A digital rendering of a human brain with highlighted neural pathways and electric activity, visualizing brain function.
18 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Pavel Burko, Ilias Miltiadis, Mahsa Alavi

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in late adolescence or early adulthood.2 The time from the first symptom to diagnosis is approximately 10–16 […]

touchLearning Activities

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
22 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: USA

Watch a leading expert discuss the key signs and symptoms of Friedreich ataxia and how to avoid diagnostic delays.

Mark CompleteCompleted
BookmarkBookmarked

Launching today, the world’s first multisector advocacy movement dedicated to stroke - the Global Stroke Action Coalition - has issued an urgent call to action to address growing inequities in stroke. Already a leading cause of death and disability, without intervention, the global burden of stroke is projected to rise by a further 50% over the next 25 years, claiming 100 million lives and costing US$1.6 trillion each year.  

Mark CompleteCompleted
BookmarkBookmarked

From 4–6 June 2025, the 20th International Forum on Mood and Anxiety Disorders (IFMAD) will take place in Budapest, Hungary, marking a significant milestone for this long-standing event in psychiatric research and practice. Since its inception in 1999, IFMAD has brought together global experts to explore the latest advances in the understanding and treatment of mood and anxiety disorders.

Mark CompleteCompleted
BookmarkBookmarked

touchNEUROLOGY is delighted to congratulate Dr Amit Bar-Or of Penn Medicine on receiving the 2025 John Dystel Prize for Multiple Sclerosis Research, jointly awarded by the National Multiple Sclerosis Society (NMMS) and the American Academy of Neurology (AAN). This honour recognizes his groundbreaking work in neuroimmunology, precision medicine, and biomarker research in multiple sclerosis (MS).

Mark CompleteCompleted
BookmarkBookmarked

Over the past two decades, the understanding and management of multiple sclerosis (MS) have advanced dramatically, reshaping long-held views of the disease. MS is now increasingly seen as a continuous spectrum rather than a condition with distinct phases, with evidence showing it can begin silently, even before clinical symptoms emerge. Technological and diagnostic innovations have enabled the detection of early brain changes and biomarkers, opening doors to earlier diagnosis and intervention. New diagnostic criteria allow MS to be identified without a clinical event, and studies on disease-modifying therapies (DMTs) support the benefits of early treatment. A major shift in treatment strategy is also underway, emphasizing early, aggressive approaches and therapies that target progression rather than just relapses, which are no longer seen as the main driver of long-term disability. A pivotal development in MS research is the confirmation of Epstein–Barr virus (EBV) as a fundamental trigger of the disease, with new evidence pointing to specific viral protein regions as higher-risk factors. Despite these strides, MS research remains a dynamic and evolving field, with much still to be uncovered beneath the surface.

Mark CompleteCompleted
BookmarkBookmarked

The 2025 Annual Meeting of the American Academy of Neurology in San Diego brought together over 14,500 neurology professionals from 110 countries and all 50 US states, alongside more than 300 exhibiting companies. It was a week filled with inspiring science, learning, and global collaboration—all in support of advancing brain health for all. Among the many highlights were the late-breaking abstracts, showcasing some of the most exciting developments in neurology. From this impressive selection, we’ve chosen five standout presentations that reflect the innovation and momentum seen throughout the meeting.

Mark CompleteCompleted
BookmarkBookmarked

In this Q&A, Herbert Temmes shares why prevention is such a crucial and timely topic, how the MS community can be more involved in shaping decisions, and what outcomes he hopes the conference will deliver for years to come.

Mark CompleteCompleted
BookmarkBookmarked

New 48-week data from the ongoing Phase 3 KINECT 4 study evaluating valbenazine for the treatment of tardive dyskinesia (TD) have been presented at the 2025 Psychiatry Update Conference in Chicago. The finding showed the majority of participants reached a defined threshold for remission of TD regardless of underlying psychiatric disorder.

Mark CompleteCompleted
BookmarkBookmarked

The FDA has approved tenecteplase (TNKase) for the treatment of acute ischemic stroke (AIS) in adults, marking the first new stroke-specific thrombolytic approval in nearly three decades. Administered as a single five-second intravenous bolus, tenecteplase allows for faster administration compared to the current standard of care alteplase, which is administered as a bolus-plus-infusion regimen.

Mark CompleteCompleted
BookmarkBookmarked

Brain Awareness Week, taking place from March 10-16, 2025, is a global campaign dedicated to fostering public enthusiasm and support for brain science, organised by the Dana Foundation. Each March, participants worldwide organize imaginative activities that highlight the wonders of the brain and the profound impact of neuroscience on our daily lives.

4 mins
Sponsored Content

Watch this short video animation to learn how genetic mutations in patients with Friedreich ataxia (FA) translate into clinical symptoms.

101 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Global
This content is sponsored by Alexion, AstraZeneca Rare Disease.

Leading experts discuss clinical evidence and real-world experience with complement inhibition therapy in the rare autoimmune disorders AChR-Ab+ gMG and AQP4-Ab+ NMOSD.

Mark CompleteCompleted
BookmarkBookmarked

The first prenatal treatment for spinal muscular atrophy showed promise in a single case report.

Mark CompleteCompleted
BookmarkBookmarked

In this Q&A, Dianne Gove, PhD, Director for Public Involvement and Ethics at Alzheimer Europe discusses the impact of stigma on the quality of life of people living with dementia, explores strategies for raising awareness and challenging misconceptions, and highlights the role of healthcare professionals and Alzheimer Europe’s key initiatives in combating stigma, including plans for 2025.

Mark CompleteCompleted
BookmarkBookmarked

The Food and Drug Administration (FDA) has approved ONAPGO™ (apomorphine hydrochloride) sublingual film for the treatment of “off” episodes in Parkinson’s disease (PD), providing patients with a new, on-demand therapy to rapidly alleviate motor symptoms when standard medications wear off.

Series of 6
Sponsored Content
touchSeries
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark, Italy
Hear from your peers about smoldering neuroinflammation and disability. Browse these important smoldering neuroinflammation topics, presented by experts in MS at key global conferences.
50 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at ECTRIMS 2024. Join MS experts as they examine disability accumulation through the lens of personalised care, biomarkers, and clinical trial design. Hear their perspectives on the complexities of balancing improved relapse management with the ongoing challenge of disability accumulation.

58 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at EAN 2024. Hear from the experts about our evolving understanding of multiple sclerosis pathophysiology and the role of smoldering neuroinflammation, with a closer look at microglia and BTK.

Load More...
touchNEUROLOGY touchNEUROLOGY

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup